Christopher Posner

Cara Therapeutics Revenue Grows 29% To $6.2M

Cara Therapeutics, Inc. (NASDAQ: CARA) released its financial results for the first quarter ended March 31, 2023, revealing revenues of $6.2 million, an increase of 29% compared to $4.8 million in Q1 2022.

Cara Therapeutics To Host Virtual R&D On March 11

Cara Therapeutics, (NASDAQ:CARA) known for its research on cannabinoid receptor agonists for the relief of inflammatory and neuropathic pain, will host a virtual research and development event on Friday, March 11 from 1:00 to 2:00 p.m.